AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: richardred who wrote (1825)	5/2/2005 9:50:41 AM
From: arnie h	Read Replies (1) of 2173

I guess the need for addt'l data for single agent therapy is what is causing short term 'investors' to bail out. Apparently they didn't do their homework well enough. There was so much speculation I assume things will be a little rocky for a bit. "Lilly executives said that while they were interested in pursuing eventual approval for Byetta as a single agent therapy, but were unsure when that application could be made. The executives added that such an approval would likely need an additional Phase III study. They said the company planned to talk to the FDA about what type of studies would be needed for such an approval."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next